Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Looks To Team Up With Shanghai Pharmaceutical To Co-develop And Commercialize Pfizer Products In China

This article was originally published in The Pink Sheet Daily

Executive Summary

The MOU with Pfizer enables the two companies to explore cooperation throughout the whole value chain, including R&D, product registration, commercialization, distribution and even manufacturing, SPH said.

You may also be interested in...

China's Outsource Sales Model Takes A Big Step: SciClone Takes Out NovaMed

SciClone Pharmaceuticals will significantly broaden its commercial footprint across China by acquiring privately owned, Shanghai-based specialty pharma NovaMed Pharmaceuticals for close to $62 million plus potential earnouts in a deal that closed April 18

China NT Pharma's Hong Kong IPO Could Trigger Consolidation In Distribution Sector

HONG KONG - China's largest vaccine promotion and sales services provider is expected to go public on the Hong Kong Stock Exchange April 20, which will likely lead to consolidation in China's distribution sector

Pfizer China Country Manager Wu Xiaobing And General Manager For Commercial And Diversified Business Kevin Xiao On Expansion To Rural Markets In China: An Interview With PharmAsia News

China recently announced it will increase its total healthcare funding for ongoing healthcare reform from RMB 850 billion ($124 billion) to RMB 1.134 trillion ($173 billion) to build up its basic medical infrastructure and expand reimbursement to more than 800 million rural residents. Pfizer Inc., the world's largest pharmaceutical company, began its geographic expansion in China seven years ago. Last year the company launched its "Spring Bud" program to expand training for rural doctors to expedite the company's entry into China's rural markets. The project initially covered the five provinces of Zhejiang, Yunnan, Fujian, Jilin and Shandong, and will now be expanded to include Guangdong, Guangxi, Sichuan, Liaoning, Henan and Hunan. In addition, Pfizer will sponsor training programs in more than 1,000 country hospitals in rural areas this year.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts